Jaap Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, offers some highlights in stem cell engineering and bone marrow transplantation (BMT) at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021. Dr Boelens describes a plenary session exploring the latest data and considerations in gene therapy and BMT for the treatment of hemoglobinopathies, as well as a international debate on the use of different transplant platforms. In addition, he discusses a plenary focused on lymphodepletion, its impact on the efficacy and toxicity of chimeric antigen receptor (CAR) T-cell therapy and data on the pharmacokinetics of these agents. This interview took place during the ISCT Annual Meeting 2021.
Disclosures
Jaap Boelens has served as a consultant for: BlueRock, Omeros, Sanofi, Advanced Clinical, AvroBio, Race Oncology and Medexus.